Meritage Portfolio Management / REGN
Meritage Portfolio Management’s Regeneron Pharmaceuticals Position
Does Meritage Portfolio Management own Regeneron Pharmaceuticals (REGN)? Yes — 20.6K shares worth $16M (+1.05% of its 13F portfolio) as of Q4 2025, down from 20.9K shares the prior filed quarter.
Position Value
$16M
Q4 2025
Shares
20.6K
% of Portfolio
+1.05%
Quarters Held
12
currently held
Position History REGN
Reported value by quarter
| Quarter | Shares | Value | % of Portfolio |
|---|---|---|---|
| Q4 2025 | 20.6K | $16M | +1.05% |
| Q3 2025 | 20.9K | $12M | +0.78% |
| Q2 2025 | 11.5K | $6M | +0.38% |
| Q1 2024 | 595 | $573,000 | +0.04% |
| Q4 2023 | 595 | $523,000 | +0.03% |
| Q3 2023 | 595 | $490,000 | +0.04% |
| Q2 2023 | 595 | $428,000 | +0.03% |
| Q1 2023 | 595 | $489,000 | +0.04% |
| Q4 2022 | 595 | $429,000 | +0.03% |
| Q3 2022 | 587 | $404,000 | +0.03% |
| Q1 2022 | 16.7K | $12M | +0.72% |
| Q2 2020 | 10.1K | $6M | +0.60% |
Common-stock position only; options are excluded. Quarters where the fund filed no 13F or reported no position are absent. See Meritage Portfolio Management’s full portfolio or all institutional holders of REGN.